|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines显示文摘AIM: To investigate the cellular defects by analyzing the (Th1/Th2) cytokine levels in vaccine responders and non-responders. METHODS: Peripheral blood mononuclear cell (PBMC) from responders and non-responders were stimulated with or with out recombinant HBsAg or PHA. Broad spectrum of cytokines viz (Th1) IFN-γ, IL-2, TNF-α, IL-12 and (Th2) IL-10, IL-4 were measured after in vitro stimulation with recombinant HBsAg and were compared with respective antibody titers. RESULTS: A significant decrease (P = 0.001) in Th1 and Th2 cytokines namely, IL-2, INF-γ, TNF-α and IL-10in non-responders was observed. The level of IL-4 was not significant between the three groups. Furthermore, despite a strong Th1 and Th2 cytokine response, the level of IL-12 was elevated in high-responders compared to other groups (P = 0.001) and demonstrated a positive correlation with anti-HBs titers and Th1 cytokine response. CONCLUSION: Our findings suggest that unrespon-siveness to recombinant hepatitis B vaccines (rHB) is multifactorial, including specific failure of antigen presentation or the lack of both T helper Th1 and Th2 response. | Vijayakumar Velu Shanmugam Saravanan Subhadra Nandakumar Esaki Muthu Shankar Appasamy Vengatesan Suresh Sakharam Jadhav Prasad Suryakant Kulkarni Sadras Panchatcharam Thyagarajan | 2008 | World Journal of Gastroenterology2008，14，22： | 22 |
| 2 | Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?显示文摘Helicobacter pylori(H. pylori) antimicrobial resistance is an urgent, global issue. In2017, the World Health Organization designated clarithromycin-resistant H.pylori as a high priority bacterium for antibiotic research and development. In addition to clarithromycin, resistance to metronidazole and fluoroquinolones has also increased worldwide. Recent international guidelines for management of H.pylori infection recommend bismuth or non-bismuth quadruple therapy for 14 d as a first-line treatment for H. pylori in areas of high clarithromycin and/or metronidazole resistance. Although these treatment regimens provide acceptable H. pylori eradication rates, the regimens used should not contribute to future resistance of H. pylori to antimicrobials. Moreover, these regimens can promote resistance, due to prolonged therapy with multiple antibiotics. A new strategy that can eradicate H. pylori as well as reduce the antibiotics used is required to prevent future antimicrobial resistance in H. pylori. Dual-therapy with vonoprazan and amoxicillin could be a breakthrough for H. pylori eradication in an era of growing antimicrobial resistance. This regimen may provide a satisfactory eradication rate of H. pylori and also minimize antimicrobial resistance due to single antibiotic use and the strong inhibitory effect of vonoprazan on gastric acid secretion. | Sho Suzuki Mitsuru Esaki Chika Kusano Hisatomo Ikehara Takuji Gotoda | 2019 | World Journal of Gastroenterology2019，25，16： | 17 |
| 3 | Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer显示文摘 | Yuji Maehata Shotaro Nakamura Kiyoshi Fujisawa Motohiro Esaki Tomohiko Moriyama Kouichi Asano Yuta Fuyuno Kan Yamaguchi Issei Egashira Hyonji Kim Motonobu Kanda Minako Hirahashi Takayuki Matsumoto | 2012 | Gastrointestinal Endoscopy2012，，1： | 10 |
| 4 | Promising biological therapies for ulcerative colitis: A review of the literature显示文摘Ulcerative colitis(UC) is a chronic lifelong condition characterized by alternating flare-ups and remission. There is no single known unifying cause, and the pathogenesis is multifactorial, with genetics, environmental factors, microbiota, and the immune system all playing roles. Current treatment modalities for UC include 5-aminosalicylates, corticosteroids, immunosuppressants(including purine antimetabolites, cyclosporine, and tacrolimus), and surgery. Therapeutic goals for UC are evolving. Medical treatment aims to induce remission and prevent relapse of disease activity. Infliximab, an anti-tumor necrosis factor(TNF)-α monoclonal antibody, is the first biological agent for the treatment of UC. Over the last decade, infliximab and adalimumab(anti-TNF-α agents) have been used for moderate to severe UC, and have been shown to be effective in inducing and maintaining remission. Recent studies have indicated that golimumab(another anti-TNF-α agent), tofacitinib(a Janus kinase inhibitor), and vedolizumab and etrolizumab(integrin antagonists), achieved good clinical remission and response rates in UC. Recently, golimumab and vedolizumab have been approved for UC by the United States Food and Drug Administration. Vedolizumab may be used as a first-line alternative to anti-TNF-α therapy in patients with an inadequate response to corticosteroids and/or immunosuppressants. Here, we provide updated information on various biological agents in the treatment of UC. | Hirotada Akiho Azusa Yokoyama Shuichi Abe Yuichi Nakazono Masatoshi Murakami Yoshihiro Otsuka Kyoko Fukawa Mitsuru Esaki Yusuke Niina Haruei Ogino | 2015 | World Journal of Gastrointestinal Pathophysiology2015，6，4： | 8 |
| 5 | Comparison of PPIs and H_2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia显示文摘AIM:To compare efficacy of proton pump inhibitors(PPIs)with H2-receptor antagonists(H2RAs)plus prokinetics(Proks)for dysmotility-like symptoms in functional dyspepsia(FD).METHODS:Subjects were randomized to receive openlabel treatment with either rabeprazole 10 mg od(n= 57)or famotidine 10 mg bid plus mosapride 5 mg tid(n=57)for 4 wk.The primary efficacy endpoint was change(%)from baseline in total dysmotility-like dyspepsia symptom score.The secondary efficacy endpoint was patient satisfaction with treatment.RESULTS:The improvement in dysmotility-like dyspep-sia symptom score on day 28 was significantly greater in the rabeprazole group(22.5%±29.2%of baseline) than the famotidine+mosapride group(53.2%± 58.6%of baseline,P<0.0001).The superior benefit of rabeprazole treatment after 28 d was consistent regardless of Helicobacter pylori status.Significantly more subjects in the rabeprazole group were satisfied or very satisfied with treatment on day 28 than in the famotidine+mosapride group(87.7%vs 59.6%,P= 0.0012).Rabeprazole therapy was the only significant predictor of treatment response(P<0.0001),defined as a total symptom score improvement≥50%.CONCLUSION:PPI monotherapy improves dysmotility-like symptoms significantly better than H2RAs plus Proks,and should be the treatment of first choice for Japanese FD. | Masahiro Sakaguchi Miyuki Takao Yasuo Ohyama Hiroshi Oka Hiroshi Yamashita Takumi Fukuchi Kiyoshi Ashida Masahiro Murotani Masuyo Murotani Kazuo Majima Hiroshi Morikawa Takashi Hashimoto Keisuke Kiyota Hirohiko Esaki Kanji Amemoto Gouhei Isowa Fumiyuki Takao | 2012 | World Journal of Gastroenterology2012，18，13： | 8 |
| 6 | Endoscopic diagnosis and treatment of superficial nonampullary duodenal tumors显示文摘The diagnostic and treatment guidelines of superficial non-ampullary duodenal tumors have not been standardized due to their low prevalence.Previous reports suggested that a superficial adenocarcinoma(SAC) should be treated via local resection because of its low risk of lymph node metastasis,whereas a highgrade adenoma(HGA) should be resected because of its high risk of progression to adenocarcinoma.Therefore,pretreatment diagnosis of SAC or HGA is important to determine the appropriate treatment strategy.There are certain endoscopic features known to be associated with SAC or HGA,and current practice prioritizes the endoscopic and biopsy diagnosis of these conditions.Surgical treatment of these duodenal lesions is often related to high risk of morbidity,and therefore endoscopic resection has become increasingly common in recent years.Endoscopic mucosal resection(EMR) and endoscopic submucosal dissection(ESD) are the commonly performed endoscopic resection methods.EMR is preferred due to its lower risk of adverse events;however,it has a higher risk of recurrence than ESD.Recently,a new and safer endoscopic procedure that reduces adverse events from EMR or ESD has been reported. | Mitsuru Esaki Sho Suzuki Hisatomo Ikehara Chika Kusano Takuji Gotoda | 2018 | World Journal of Gastrointestinal Endoscopy2018，10，9： | 7 |
| 7 | Measurement of prostaglandin metabolites is useful in diagnosis of small bowel ulcerations显示文摘BACKGROUND We recently reported on a hereditary enteropathy associated with a gene encoding a prostaglandin transporter and referred to as chronic enteropathy associated with SLCO2 A1 gene(CEAS). Crohn's disease(CD) is a major differential diagnosis of CEAS, because these diseases share some clinical features. Therefore, there is a need to develop a convenient screening test to distinguish CEAS from CD.AIM To examine whether prostaglandin E major urinary metabolites(PGE-MUM) can serve as a biomarker to distinguish CEAS from CD.METHODS This was a transactional study of 20 patients with CEAS and 98 patients with CD.CEAS was diagnosed by the confirmation of homozygous or compound heterozygous mutation of SLCO2 A1. We measured the concentration of PGEMUM in spot urine by radioimmunoassay, and the concentration was compared between the two groups of patients. We also determined the optimal cut-off value of PGE-MUM to distinguish CEAS from CD by receiver operating characteristic(ROC) curve analysis.RESULTS Twenty Japanese patients with CEAS and 98 patients with CD were enrolled.PGE-MUM concentration in patients with CEAS was significantly higher than that in patients with CD(median 102.7 vs 27.9 μg/g × Cre, P < 0.0001). One log unit increase in PGE-MUM contributed to 7.3 increase in the likelihood for the diagnosis of CEAS [95% confidence interval(CI) 3.2-16.7]. A logistic regression analysis revealed that the association was significant even after adjusting confounding factors(adjusted odds ratio 29.6, 95%CI 4.7-185.7). ROC curve analysis revealed the optimal PGE-MUM cut-off value for the distinction of CEAS from CD to be 48.9 μg/g × Cre with 95.0% sensitivity and 79.6% specificity.CONCLUSION PGE-MUM measurement is a convenient, non-invasive and useful test for the distinction of CEAS from CD. | Yuichi Matsuno Junji Umeno Motohiro Esaki Yoichiro Hirakawa Yuta Fuyuno Yasuharu Okamoto Atsushi Hirano Shigeyoshi Yasukawa Fumihito Hirai Toshiyuki Matsui Shuhei Hosomi Kenji Watanabe Naoki Hosoe Haruhiko Ogata Tadakazu Hisamatsu Shunichi Yanai Shuji Kochi Koichi Kurahara Tsuneyoshi Yao Takehiro Torisu Takanari Kitazono Takayuki Matsumoto | 2019 | World Journal of Gastroenterology2019，25，14： | 5 |
| 8 | Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma显示文摘As a result of donor shortage and high postoperative morbidity and mortality after liver transplantation,hepatectomy is the most widely applicable and reliable option for curative treatment of hepatocellular carcinoma(HCC).Because intrahepatic tumor recurrence is frequent after loco-regional therapy,repeated treatments are advocated provided background liver function is maintained.Among treatments including local ablation and transarterial chemoembolization,hepatectomy provides the best long-term outcomes,but studies comparing hepatectomy with other nonsurgical treatments require careful review for selection bias.In patients with initially unresectable HCC,transarterial chemo-or radio-embolization,and/or systemic chemotherapy can down-stage the tumor and conversion to resectable HCC is achieved in approximately 20%of patients.However,complete response is rare,and salvage hepatectomy is essential to help prolong patients’survival.To counter the short recurrence-free survival,excellent overall survival is obtained by combining and repeating different treatments.It is important to recognize hepatectomy as a complement,rather than a contraindication,to other nonsurgical treatments in a mul-tidisciplinary approach for patients with HCC,including recurrent or unresectable tumors. | Yoji Kishi Kazuaki Shimada Satoshi Nara Minoru Esaki Tomoo Kosuge | 2014 | World Journal of Hepatology2014，6，12： | 5 |
| 9 | GIS COMPONENT BASED 3D LANDSLIDE HAZARD ASSESSMENT SYSTEM: 3DSLOPEGIS显示文摘In this paper, based on a new Geographic Information System (GIS) grid-based three-dimensional (3D) deterministic model and taken the slope unit as the study object, the landslide hazard is mapped by the index of the 3D safety factor. Compared with the one-dimensional (1D) model of infinite slope, which is now widely used for deterministic model based landslide hazard assessment in GIS, the GIS grid-based 3D model is more acceptable and is more adaptable for three-dimensional landslide. Assuming the initial slip as the lower part of an ellipsoid, the 3D critical slip surface in the 3D slope stability analysis is obtained by means of a minimization of the 3D safety factor using the Monte Carlo random simulation. Using a hydraulic model tool for the watershed analysis in GIS, an automatic process has been developed for identifying the slope unit from digital elevation model (DEM) data. Compared with the grid-based landslide hazard mapping method, the slope unit possesses clear topographical meaning, so its results are more credible. All the calculations are implemented by a computational program, 3DSlopeGIS, in which a GIS component is used for fulfilling the GIS spatial analysis function, and all the data for the 3D slope safety factor calculation are in the form of GIS data (the vector and the grid layers). Because of all these merits of the GIS-based 3D landslide hazard mapping method, the complex algorithms and iteration procedures of the 3D problem can also be perfectly implemented. | XIE Mo-wen, ZHOU Guo-yun, ESAKI Tetsuro(Institute of Environmental Systems, Kyushu University, Hakozaki 6-10-1, Higashi Ku, Fukuoka, 812-8581, Japan) | 2003 | Chinese Geographical Science2003，13，1： | 4 |
| 10 | Efficacy of a Hepatectomy and a Tumor Thrombectomy for Hepatocellular Carcinoma with Tumor Thrombus Extending to the Main Portal Vein显示文摘 | Daisuke Ban Kazuaki Shimada Yusuke Yamamoto Satoshi Nara Minoru Esaki Yoshihiro Sakamoto Tomoo Kosuge | 2009 | Journal of Gastrointestinal Surgery2009，，11： | 4 |
| 11 | 手术中知晓事件的新分级标准显示文摘背景有外显记忆的手术中知晓事件的发生率仅为1/1000—2/1000。因其较罕见,为了更好的了解手术中知晓事件及其后遗效直,需要对大批量的研究数据进行统计。因此,对其进行标准描述和表达将很有价值。方法本研究创建了一种新的手术中知晓事件评估标准:0级:未发生手术中知晓;1级:仅存在听觉感知;2级:感知触觉(比如手术操作、气管插管);3级:感知痛觉;4级:感知麻痹(比如感到不能活动、说话或呼吸);5级:感知麻痹及痛觉。患者主述有恐惧、焦虑、窒息、末日感、濒死感及其他相关显性描述,另行附加“D”(distress[痛苦、悲伤])。本研究回顾了15项详细提供手术中知晓报告信息的研究。来自3个研究并创建了该项分级标准的5位麻醉医生,各自独立的评估了这些病例。另外20名相关人员(麻醉主治医生、麻醉住院医生、麻醉护士、医学生及其辅助工作人员),虽未参与该分级标准的创建,但也独立对手术中知晓事件进行了评估。用Flwiss’s κ系数评估观察者之间的一致性。结果对151例确认发生手术中知晓事件的成年病例进行数据分析。基础评估1~5级中,总体κ系数为0.851(95%可信区间CI0.847~0.856)。包括附加情感障碍“D”的评估中,总体κ系数为0.779(95%可信区间CI 0.776~0.783)。结论本研究创建了新的手术中知晓事件评估标准,在评估者间具有近乎完美的一致性,这将有助于手术中知晓事件的研究。 | George A. Mashour Roy K. Esaki Kevin K. Tremper David B. Glick Michael O'Connor Michael S. Avidan 潘鹏(译) 李文志(校) | 2009 | 麻醉与镇痛2009，，6： | 3 |
| 12 | Advanced technology for the improvement of adenoma and polyp detection during colonoscopy显示文摘 | Tomohiko Moriyama Toshio Uraoka Motohiro Esaki Takayuki Matsumoto | 2015 | Digestive Endoscopy2015，，： | 2 |
| 13 | Left hepatic trisectionectomy for advanced perihilar cholangiocarcinoma显示文摘 | M. Esaki K. Shimada S. Nara Y. Kishi Y. Sakamoto T. Kosuge T. Sano | 2013 | Br J Surg2013，，6： | 2 |
| 14 | Endoscopic resection for residual lesion of metastatic gastric cancer:A case report显示文摘BACKGROUND Chemotherapy is a standard strategy for stage IV gastric cancer patients.However, some cases cannot undergo conversion surgery because of their frailty,even if the patients had response to chemotherapy. For these patients, local tumor progression is a problem. We report here the case of a patient whose residual gastric cancer was resected through endoscopic submucosal dissection(ESD)after concomitant chemotherapy for metastatic gastric cancer.CASE SUMMARY An 85-year-old male complained of difficulty swallowing, and examination revealed gastric cancer with multiple liver metastases. Although he received concomitant chemotherapy, a residual tumor was observed in the primary lesion while the metastatic lesions disappeared completely. Conversion surgery was considered optional treatment; however, he could not undergo that because of advanced age and comorbidities. Thus, we performed ESD to treat the residual tumor. As a result, we resected the residual lesion completely. The patient has been alive for 29 mo since ESD, without recurrence.CONCLUSION We achieved local control using ESD, and these findings may provide therapeutic improvements both in local control and patient survival outcomes. | Kaori Hayashi Sho Suzuki Hisatomo Ikehara Hiroaki Okuno Akira Irie Mitsuru Esaki Chika Kusano Takuji Gotoda Mitsuhiko Moriyama | 2019 | World Journal of Clinical Cases2019，7，4： | 2 |
| 15 | Endoscopic mucosal resection vs endoscopic submucosal dissection for superficial non-ampullary duodenal tumors显示文摘BACKGROUND The selection of endoscopic treatments for superficial non-ampullary duodenal epithelial tumors(SNADETs)is controversial.AIM To compare the efficacy and safety of endoscopic mucosal resection(EMR)and endoscopic submucosal dissection(ESD)for SNADETs.METHODS We retrospectively analyzed the data of patients with SNADETs from a database of endoscopic treatment for SNADETs,which included eight hospitals in Fukuoka,Japan,between April 2001 and October 2017.A total of 142 patients with SNADETs treated with EMR or ESD were analyzed.Propensity score matching was performed to adjust for the differences in the patient characteristics between the two groups.We analyzed the treatment outcomes,including the rates of en bloc/complete resection,procedure time,adverse event rate,hospital stay,and local or metastatic recurrence.RESULTS Twenty-eight pairs of patients were created.The characteristics of patients between the two groups were similar after matching.The EMR group had a significantly shorter procedure time and hospital stay than those of the ESD group[median procedure time(interquartile range):6(3-10.75)min vs 87.5(68.5-136.5)min,P<0.001,hospital stay:8(6-10.75)d vs 11(8.25-14.75)d,P=0.006].Other outcomes were not significantly different between the two groups(en bloc resection rate:82.1%vs 92.9%,P=0.42;complete resection rate:71.4%vs 89.3%,P=0.18;and adverse event rate:3.6%vs 17.9%,P=0.19,local recurrence rate:3.6%vs 0%,P=1;metastatic recurrence rate:0%in both).Only one patient in the ESD group underwent emergency surgery owing to intraoperative perforation.CONCLUSION EMR has significantly shorter procedure time and hospital stay than ESD,and provides acceptable curability and safety compared to ESD.Accordingly,EMR for SNADETs is associated with lower medical costs. | Mitsuru Esaki Kazuhiro Haraguchi Kazuya Akahoshi Naru Tomoeda Akira Aso Soichi Itaba Haruei Ogino Yusuke Kitagawa Hiroyuki Fujii Kazuhiko Nakamura Masaru Kubokawa Naohiko Harada Yosuke Minoda Sho Suzuki Eikichi Ihara Yoshihiro Ogawa | 2020 | World Journal of Gastrointestinal Oncology2020，12，8： | 2 |
| 16 | Factors Associated with the Clinical Impact of Capsule Endoscopy in Patients with Overt Obscure Gastrointestinal Bleeding显示文摘 | Motohiro Esaki Takayuki Matsumoto Shinichiro Yada Ritsuko Yanaru-Fujisawa Tetsuji Kudo Shunichi Yanai Shotaro Nakamura Mitsuo Iida | 2010 | Digestive Diseases and Sciences2010，，8： | 2 |
| 17 | Mucosal vascular pattern in ulcerative colitis: observations using narrow band imaging colonoscopy with special reference to histologic inflammation显示文摘 | Tetsuji Kudo Takayuki Matsumoto Motohiro Esaki Takashi Yao Mitsuo Iida | 2009 | International Journal of Colorectal Disease2009，，5： | 2 |
| 18 | Genetic analysis is helpful for the diagnosis of small bowel ulceration显示文摘The widespread use of capsule endoscopy and balloonassisted endoscopy has provided easy access for detailed mucosal assessment of the small intestine. However, the diagnosis of rare small bowel diseases, such as cryptogenic multifocal ulcerous stenosing enteritis(CMUSE), remains difficult because clinical and morphological features of these diseases are obscure even for gastroenterologists. In an issue of this journal in 2017, Hwang et al reviewed and summarized clinical and radiographic features of 20 patients with an established diagnosis of CMUSE. Recently, recessive mutations in the PLA2G4A and SLCO2A1 genes have been shown to cause small intestinal diseases. The small bowel ulcers in each disease mimic those in the other and furthermore those found in nonsteroidal anti-inflammatory drug-induced enteropathy. These recent and novel findings suggest that a clinical diagnosis exclusively based on the characteristics of small bowel lesions is possibly imprecise. Genetic analyses seem to be inevitable for the diagnosis of rare small bowel disorders such as CMUSE. | Junji Umeno Takayuki Matsumoto Atsushi Hirano Yuta Fuyuno Motohiro Esaki | 2018 | World Journal of Gastroenterology2018，24，28： | 2 |
| 19 | Sciatic nerve regeneration in rats induces by transplantation of in vitro differentiated bone-marrow stromal cells显示文摘 | Dezawa M Takahashi L Esaki M | 2001 | European J Neurosci2001，14，1： | 1 |
| 20 | 显示文摘 | Esaki H Ameyama K Tokizane M | 1989 | Mater Sci Tech1989，5，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员